Cantargia AB logo

CANTA BTA - Cantargia AB News Story

SEK7.34 0.0  0.0%

Last Trade - 11/01/18

Sector
Healthcare
Size
Small Cap
Market Cap £186.6m
Enterprise Value £143.1m
Revenue £n/a
Position in Universe th / 1782

BRIEF-Cantargia AB - Cantargia Presents New Preclinical Data

Fri 15th May, 2020 7:42am
May 15 (Reuters) - Cantargia AB  CANTA.ST :
    * CANTARGIA AB - CANTARGIA PRESENTS NEW PRECLINICAL DATA ON CAN04 IN COMBINATION WITH
CHEMOTHERAPY
AT THE 2020 AACR ANNUAL MEETING
    * CANTARGIA AB - ANTIBODY CAN04 BINDS IL1RAP WITH HIGH AFFINITY AND FUNCTIONS THROUGH BOTH
ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY (ADCC) AND BLOCKADE OF INTERLEUKIN-1 SIGNALING
    * CANTARGIA AB - RESULTS SHOW SYNERGISTIC/ADDITIVE EFFECTS OF COMBINING CAN04 WITH THREE
DIFFERENT
REGISTERED PLATINUM-BASED THERAPIES
    * CANTARGIA AB - A PHASE I TRIAL INVESTIGATING CAN04 IN COMBINATION WITH AN IMMUNE
CHECKPOINT
INHIBITOR IS PLANNED TO START DURING 2020.
    * CANTARGIA AB - NEW DATA IS PRESENTED SHOWING POTENT EFFECTS OF CAN04 WITH CISPLATIN ON
TUMOR
GROWTH IN A NOVEL ZEBRAFISH XENOGRAFT SCREENING SYSTEM FOR ANTI-CANCER DRUGS

Source text for Eikon:  ID:nNDL5pS0Qk 
Further company coverage:  CANTA.ST 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.